Gas gangrene: an open and closed case

References

1. Alape-Giron A., Flores-Diaz M., Guillouard I. 8 other authors 2000; Identification of residues critical for toxicity in Clostridium perfringens phospholipase C, the key toxin in gas gangrene. Eur J Biochem 267:5191–5197 [CrossRef]
   [Google Scholar]
2. Awad M. M., Bryant A. E., Stevens D. L., Rood J. I. 1995; Virulence studies on chromosomal alpha-toxin and theta-toxin mutants constructed by allelic exchange provide genetic evidence for the essential role of alpha-toxin in Clostridium perfringens -mediated gas-gangrene. Mol Microbiol 15:191–202 [CrossRef]
   [Google Scholar]
3. Barker A. P., Vasil A. I., Filloux A., Ball G., Wilderman P. J., Vasil M. L. 2004; A novel extracellular phospholipase C of Pseudomonas aeruginosa is required for phospholipid chemotaxis. Mol Microbiol 53:1089–1098 [CrossRef]
   [Google Scholar]
4. Basak A. K., Stuart D. I., Nikura T., Bishop D. H. L., Kelly D. C., Fearn A., Titball R. W. 1994; Purification, crystallization and preliminary X-ray diffraction studies of alpha-toxin of Clostridium perfringens . J Mol Biol 244:648–650 [CrossRef]
   [Google Scholar]
5. Bowman S. 1998 Iraqi Chemical and Biological Weapons (CBW) Capabilities pp 1–5 Washington, DC: Congressional Research Service;
   [Google Scholar]
6. Boyd N. A., Thomson R. O., Walker P. D. 1972; The prevention of experimental Clostridium novyi and Cl. perfringens gas gangrene in high-velocity missile wounds by active immunisation. J Med Microbiol 5:467–472 [CrossRef]
   [Google Scholar]
7. Bramley A. J., Patel A. H., O'Reilly M., Foster R., Foster T. J. 1989; Roles of alpha-toxin and beta-toxin in virulence of Staphylococcus aureus for the mouse mammary gland. Infect Immun 57:2489–2494
   [Google Scholar]
8. Bryant A. E., Chen R. Y. Z., Nagata Y., Wang Y., Lee C. H., Finegold S., Guth P. H., Stevens D. L. 2000a; Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens . J Infect Dis 182:799–807 [CrossRef]
   [Google Scholar]
9. Bryant A. E., Chen R. Y. Z., Nagata Y., Wang Y., Lee C. H., Finegold S., Guth P. H., Stevens D. L. 2000b; Clostridial gas gangrene. II. Phospholipase C-induced activation of platelet gpIIbIIIa mediates vascular occlusion and myonecrosis in Clostridium perfringens gas gangrene. J Infect Dis 182:808–815 [CrossRef]
   [Google Scholar]
10. Clark G. C., Briggs D., Karasawa T. 10 other authors 2003; Clostridium absonum α -toxin – new insights into clostridial phospholipase C substrate binding and specificity. J Mol Biol 333:759–769 [CrossRef]
    [Google Scholar]
11. Cordesman A. H. 1998 UNSCOM Main Achievements: United Nations Special Commission (UNSCOM) pp 67–71 New York: United Nations;
    [Google Scholar]
12. Cygan Z. 1997; Properties, mechanisms of action and pathogenic role of alpha-toxin C. perfringens – a review. Med Weter 53:73–76
    [Google Scholar]
13. Darwin A. J., Miller V. L. 1999; Identification of Yersinia enterocolitica genes affecting survival in an animal host using signature-tagged transposon mutagenesis. Mol Microbiol 32:51–62 [CrossRef]
    [Google Scholar]
14. Eaton J. T., Naylor C. E., Howells A. M., Moss D. S., Titball R. W., Basak A. K. 2002; Crystal structure of the C. perfringens alpha-toxin with the active site closed by a flexible loop region. J Mol Biol 319:275–281 [CrossRef]
    [Google Scholar]
15. Evans D. G. 1945; The in-vitro production of alpha-toxin, theta-haemolysin and hyaluronidase by strains of Cl. welchii type A, and the relationship of in-vitro properties to virulence for guinea-pigs. J Pathol Bacteriol 57:77–85
    [Google Scholar]
16. Flores-Diaz M., Alape-Giron A., Titball R. W. 7 other authors 1998; UDP-glucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium perfringens phospholipase C. J Biol Chem 273:24433–24438 [CrossRef]
    [Google Scholar]
17. Fujii Y., Sakurai J. 1989; Contraction of the rat isolated aorta caused by Clostridium perfringens alpha toxin (phospholipase-C) – evidence for the involvement of arachidonic acid metabolism. Br J Pharmacol 97:119–124 [CrossRef]
    [Google Scholar]
18. Fujii Y., Shirotani M., Sakurai J. 1986; Effect of Clostridium perfringens alpha-toxin on rabbit platelets. Jpn J Med Sci Biol 39:244–245
    [Google Scholar]
19. Ginter A., Williamson E. D., Dessy F., Coppe P., Bullifent H., Howells A., Titball R. W. 1996; Molecular variation between the alpha-toxins from the type strain (NCTC 8237) and clinical isolates of Clostridium perfringens associated with disease in man and animals. Microbiology 142:191–198 [CrossRef]
    [Google Scholar]
20. Granström M., Erickson A., Strandvik B., Wretlind B., Pavlovskis O. R., Berka R., Vasil M. 1984; Relationship between antibody response to Pseudomonas aeruginosa exoproteins and colonisation/infection in patients with cystic fibrosis. Acta Paediatr Scand 73:772–777 [CrossRef]
    [Google Scholar]
21. Grave K., Kaldhusdal M. C., Kruse H., Harr L. M., Flatlandsmo K. 2004; What has happened in Norway after the ban of avoparcin? Consumption of antimicrobials by poultry. Prev Vet Med 62:59–72 [CrossRef]
    [Google Scholar]
22. Guillouard I., Garnier T., Cole S. T. 1996; Use of site-directed mutagenesis to probe structure-function relationships of alpha-toxin from Clostridium perfringens . Infect Immun 64:2440–2444
    [Google Scholar]
23. Gustafson C., Tagesson C. 1990; Phospholipase-C from Clostridium perfringens stimulates phospholipase-A2-mediated arachidonic acid release in cultured intestinal epithelial cells (Int-407). Scand J Gastroenterol 25:363–371
    [Google Scholar]
24. Heier B. T., Lovland A., Soleim K. B., Kaldhusdal M., Jarp J. 2001; A field study of naturally occurring specific antibodies against Clostridium perfringens alpha toxin in Norwegian broiler flocks. Avian Dis 45:724–732 [CrossRef]
    [Google Scholar]
25. Hinnebusch B. J., Rudolph A. E., Cherepanov P., Dixon J. E., Schwan T. G., Forsberg A. 2002; Role of Yersinia murine toxin in survival of Yersinia pestis in the midgut of the flea vector. Science 296:733–735 [CrossRef]
    [Google Scholar]
26. Hodgson A. L., Krywult J., Corner L. A., Rothel J. S., Radford A. J. 1992; Rational attenuation of Corynebacterium pseudotuberculosis : potential cheesy gland vaccine and live delivery vehicle. Infect Immun 60:2900–2905
    [Google Scholar]
27. Holm B. A., Keicher L., Liu M., Sokolowski J., Enhorning G. 1991; Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 71:317–321
    [Google Scholar]
28. Justin N., Walker N. 8 other authors Bullifent H. L. 2002; The first strain of Clostridium perfringens isolated from an avian source has an alpha-toxin with divergent structural and kinetic properties. Biochemistry 41:6253–6262 [CrossRef]
    [Google Scholar]
29. Kameyama S., Sato H., Murata R. 1975; The role of α -toxin of Clostridium perfringens in experimental gas gangrene in guinea pigs. Jpn J Med Sci Biol 25:200
    [Google Scholar]
30. Karlyshev A. V., Oyston P. C., Williams K., Clark G. C., Titball R. W., Winzeler E. A., Wren B. W. 2001; Application of high-density array-based signature-tagged mutagenesis to discover novel yersinia virulence-associated genes. Infect Immun 69:7810–7819 [CrossRef]
    [Google Scholar]
31. König B., Vasil M. L., König W. 1997; Role of hemolytic and nonhemolytic phospholipase C from Pseudomonas aeruginosa for inflammatory mediator release from human granulocytes. Int Arch Allergy Immunol 112:115–124 [CrossRef]
    [Google Scholar]
32. Krug E. L., Kent C. 1984; Phospholipase C from Clostridium perfringens : preparation and characterisation of homogenous enzyme. Arch Biochem Biophys 231:400–410 [CrossRef]
    [Google Scholar]
33. Langton S. R., Cesareo S. D. 1992; Helicobacter pylori associated phospholipase A2 activity: a factor in peptic ulcer production. J Clin Pathol 45:221–224 [CrossRef]
    [Google Scholar]
34. Lovland A., Kaldhusdal M., Redhead K., Skjerve E., Lillehaug A. 2004; Maternal vaccination against subclinical necrotic enteritis in broilers. Avian Pathol 33:83–92
    [Google Scholar]
35. MacFarlane M. G. 1955 On the Biochemical Mechanisms of Action of Gas Gangrene Toxins Cambridge: Cambridge University Press;
    [Google Scholar]
36. MacLennan J. D. 1962; The histotoxic clostridial infections of man. Bacteriol Rev 26:177–276
    [Google Scholar]
37. MacLennan J. D., MacFarlane M. G. 1944; The treatment of gas gangrene. Br Med J II 683:
    [Google Scholar]
38. McNamara P. J., Bradley G. A., Songer J. G. 1994; Targeted mutagenesis of the phospholipase D gene results in decreased virulence of Corynebacterium pseudotuberculosis . Mol Microbiol 12:921–930 [CrossRef]
    [Google Scholar]
39. McNee J. W., Dunn J. S. 1917; The method of spread of gas gangrene into living muscle. Br Med J 1:727–729
    [Google Scholar]
40. Nagahama M., Nakayama T., Kobayashi K., Sakurai J. 1995a; Site-directed mutagenesis studies on the zinc-binding domain of Clostridium perfringens alpha toxin. Jpn J Med Sci Biol 48:265–266
    [Google Scholar]
41. Nagahama M., Ochi S., Kobayashi K., Sakurai J. 1995b; The relationship between histidine residues and various biological activities of Clostridium perfringens alpha-toxin. Abstr Pap Am Chem Soc 209:75–AGFD
    [Google Scholar]
42. Nagahama M., Nakayama T., Michiue K., Sakurai J. 1997; Site-specific mutagenesis of Clostridium perfringens alpha-toxin: replacement of Asp-56, Asp-130, or Glu-152 causes loss of enzymatic and hemolytic activities. Infect Immun 65:3489–3492
    [Google Scholar]
43. Naylor C. E., Eaton J. T., Howells A., Justin N., Moss D. S., Titball R. W., Basak A. K. 1998; Structure of the key toxin in gas gangrene. Nat Struct Biol 5:738–746 [CrossRef]
    [Google Scholar]
44. Naylor C. E., Jepson M., Crane D. T., Titball R. W., Miller J., Basak A. K., Bolgiano B. 1999; Characterisation of the calcium-binding C-terminal domain of Clostridium perfringens alpha-toxin. J Mol Biol 294:757–770 [CrossRef]
    [Google Scholar]
45. Ohsaka A., Tsuchiya M., Oshio C., Miyaira M., Suzuki K., Yamkawa Y. 1978; Aggregation of platelets in the micro-circulation of the rat induced by the alpha-toxin (phospholipase C) of Clostridium perfringens . Toxicon 16:333–341 [CrossRef]
    [Google Scholar]
46. Ottlecz A., Romero J. J., Hazell S. L., Graham D. Y., Lichtenberger L. M. 1993; Phospholipase activity of Helicobacter pylori and its inhibition by bismuth salts. Dig Dis Sci 38:2071–2080 [CrossRef]
    [Google Scholar]
47. Rahme L. G., Stevens E. J., Wolfort S. F., Shao J., Tompkins R. G., Ausubel F. M. 1995; Common virulence factors for bacterial pathogenicity in plants and animals. Science 268:1899–1902 [CrossRef]
    [Google Scholar]
48. Raynaud C., Guilhot C., Rauzier J., Bordat Y., Pelicic V., Manganelli R., Smith I., Gicquel B., Jackson M. 2002; Phospholipases C are involved in the virulence of Mycobacterium tuberculosis . Mol Microbiol 45:203–217 [CrossRef]
    [Google Scholar]
49. Saiman L., Cacalano G., Gruenert D., Prince A. 1992; Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun 60:2808–2814
    [Google Scholar]
50. Samuelsson B. 1983; Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220:568–575 [CrossRef]
    [Google Scholar]
51. Sato H., Frank D. W. 2004; ExoU is a potent intracellular phospholipase. Mol Microbiol 53:1279–1290 [CrossRef]
    [Google Scholar]
52. Sheedy S. A., Ingham A. B., Rood J. I., Moore R. J. 2004; Highly conserved alpha-toxin sequences of avian isolates of Clostridium perfringens . J Clin Microbiol 42:1345–1347 [CrossRef]
    [Google Scholar]
53. Shortridge V. D., Lazdunski A., Vasil M. L. 1992; Osmoprotectants and phosphate regulate expression of phospholipase C in Pseudomonas aeruginosa . Mol Microbiol 6:863–871 [CrossRef]
    [Google Scholar]
54. Smith G. A., Marquis H., Jones S., Johnston N. C., Portnoy D. A., Goldfine H. 1995; The two distinct phospholipases C of Listeria monocytogenes have overlapping roles in escape from a vacuole and cell-to-cell spread. Infect Immun 63:4231–4237
    [Google Scholar]
55. Songer J. G. 2002; Gas gangrene and myonecrosis. In Molecular Genetics, Classification, Pathology and Ecology of the Genus Clostridium pp 53–62 Edited by Duchesnes C., Mainil J. Liège: Presses de la Faculté de Médecine Vétérinaire de l'Université de Liège;
    [Google Scholar]
56. Stevens D. L., Titball R. W., Jepson M., Bayer C., Schroer S., Bryant A. E. 2004; Immunization with C-domain of alpha-toxin prevents lethal infection, localizes tissue injury and promotes host response to challenge with viable Clostridium perfringens . J Infect Dis 190:767–773 [CrossRef]
    [Google Scholar]
57. Sugahara T., Takahashi T., Yamaya S., Ohsaka A. 1977; In vitro aggregation of platelets induced by alpha-toxin (phospholipase C) of Clostridium perfringens . Jpn J Med Sci Biol 29:255–263
    [Google Scholar]
58. Titball R. W. 1999; Membrane-damaging and cytotoxic phospholipases. In The Comprehensive Sourcebook of Bacterial Protein Toxins pp 310–329 Edited by Alouf J. E., Freer J. H. London: Academic Press;
    [Google Scholar]
59. Titball R. W., Rood J. I. 1999; Bacterial phospholipases. In Bacterial Protein Toxins pp 529–556 Edited by Aktories K., Just I. Berlin, Heidelberg, New York: Springer;
    [Google Scholar]
60. Titball R. W., Rubidge T. 1990; The role of histidine residues in the alpha toxin of Clostridium perfringens . FEMS Microbiol Lett 68:261–265
    [Google Scholar]
61. Titball R. W., Hunter S. E. C., Martin K. L., Morris B. C., Shuttleworth A. D., Rubidge T., Anderson D. W., Kelly D. C. 1989; Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase-C) of Clostridium perfringens . Infect Immun 57:367–376
    [Google Scholar]
62. Titball R. W., Leslie D. L., Harvey S., Kelly D. 1991; Hemolytic and sphingomyelinase activities of Clostridium perfringens alpha-toxin are dependent on a domain homologous to that of an enzyme from the human arachidonic acid pathway. Infect Immun 59:1872–1874
    [Google Scholar]
63. Titball R. W., Fearn A. M., Williamson E. D. 1993; Biochemical and immunological properties of the C-terminal domain of the alpha-toxin of Clostridium perfringens . FEMS Microbiol Lett 110:45–50 [CrossRef]
    [Google Scholar]
64. Tsutsui K., Minami J., Matsushita O., Katayama S., Taniguchi Y., Nakamura S., Nishioka M., Okabe A. 1995; Phylogenetic analysis of phospholipase-C genes from Clostridium perfringens Type-A to Type-E and Clostridium novyi . J Bacteriol 177:7164–7170
    [Google Scholar]
65. Van Immerseel F., De Buck J., Pasmans F., Huyghebaert G., Haesebrouck F., Ducatelle R. 2004; Clostridium perfringens in poultry: an emerging threat for animal and public health. Avian Pathol 33:537–549 [CrossRef]
    [Google Scholar]
66. Walker N., Holley J., Naylor C. E. 10 other authors 2000; Identification of residues in the carboxy-terminal domain of Clostridium perfringens alpha-toxin (phospholipase C) which are required for its biological activities. Arch Biochem Biophys 384:24–30 [CrossRef]
    [Google Scholar]
67. Wierup M. 2001; The Swedish experience of the 1986 year ban of antimicrobial growth promoters, with special reference to animal health, disease prevention, productivity, and usage of antimicrobials. Microb Drug Resist 7:183–190 [CrossRef]
    [Google Scholar]
68. Williamson E. D., Titball R. W. 1993; A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas-gangrene. Vaccine 11:1253–1258 [CrossRef]
    [Google Scholar]